Katie Robinson, Simon J Cooper, Sasha Persaud, Jennifer L Frederick, Rishi P Singh
{"title":"Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections.","authors":"Katie Robinson, Simon J Cooper, Sasha Persaud, Jennifer L Frederick, Rishi P Singh","doi":"10.2147/OPTH.S532179","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To determine how patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) perceive their disease and its treatment and to assess the degree of alignment between patient and clinician perceptions.</p><p><strong>Patients and methods: </strong>In June 2024 a survey of 101 patients (50 with DME and 51 with nAMD) and 100 ophthalmologists who treat these conditions completed surveys.</p><p><strong>Results: </strong>Sixty-six percent and 86% of patients with DME and nAMD, respectively, reported receiving intravitreal injections at least once every 8 weeks. Eighty-two percent required a caregiver and/or public transportation to get to their appointments. The most significant symptoms for patients with DME were vision loss over time (2.89 out of 4.0) and blurred or double vision (2.76), and for those with nAMD were poor night vision (3.43), seeing in low-light conditions (3.27), and blurred vision (2.96). The proportion of patients who were dissatisfied with the education and counseling they received about their disease was greater for nAMD (31%) compared with DME (11%; <i>P</i> < 0.01). Ophthalmologists overestimated the extent to which patients perceived that injections were necessary (mean Likert scale score 3.41 vs 3.00; <i>P</i> < 0.01) and that patients experienced insurance barriers to receiving treatment (3.00 vs 2.46; <i>P</i> < 0.01). They overestimated the extent to which patients became less nervous with subsequent injections after the first (3.40 vs 2.94; <i>P</i> < 0.01) and underestimated their difficulty of getting to appointments (2.30 vs 2.64; <i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>This study highlights the significant burden experienced by patients undergoing intravitreal injections and identifies key areas of discordance between patient and clinician perceptions. Targeted education and counseling focused on these differences is indicated to improve patient satisfaction and outcomes.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"2637-2645"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341839/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S532179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To determine how patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) perceive their disease and its treatment and to assess the degree of alignment between patient and clinician perceptions.
Patients and methods: In June 2024 a survey of 101 patients (50 with DME and 51 with nAMD) and 100 ophthalmologists who treat these conditions completed surveys.
Results: Sixty-six percent and 86% of patients with DME and nAMD, respectively, reported receiving intravitreal injections at least once every 8 weeks. Eighty-two percent required a caregiver and/or public transportation to get to their appointments. The most significant symptoms for patients with DME were vision loss over time (2.89 out of 4.0) and blurred or double vision (2.76), and for those with nAMD were poor night vision (3.43), seeing in low-light conditions (3.27), and blurred vision (2.96). The proportion of patients who were dissatisfied with the education and counseling they received about their disease was greater for nAMD (31%) compared with DME (11%; P < 0.01). Ophthalmologists overestimated the extent to which patients perceived that injections were necessary (mean Likert scale score 3.41 vs 3.00; P < 0.01) and that patients experienced insurance barriers to receiving treatment (3.00 vs 2.46; P < 0.01). They overestimated the extent to which patients became less nervous with subsequent injections after the first (3.40 vs 2.94; P < 0.01) and underestimated their difficulty of getting to appointments (2.30 vs 2.64; P < 0.01).
Conclusion: This study highlights the significant burden experienced by patients undergoing intravitreal injections and identifies key areas of discordance between patient and clinician perceptions. Targeted education and counseling focused on these differences is indicated to improve patient satisfaction and outcomes.
目的:确定患有新生血管性年龄相关性黄斑变性(nAMD)或糖尿病性黄斑水肿(DME)的患者如何看待他们的疾病及其治疗,并评估患者和临床医生看法的一致性程度。患者和方法:2024年6月,对101例患者(50例DME和51例nAMD)和100名治疗这些疾病的眼科医生进行了调查。结果:66%和86%的DME和nAMD患者分别报告每8周至少接受一次玻璃体内注射。82%的人需要护理人员和/或公共交通工具才能到达他们的约会地点。DME患者最显著的症状是视力减退(2.89分,满分4.0分)和模糊或重影(2.76分),而nAMD患者的症状是夜视差(3.43分)、弱光条件下视力(3.27分)和模糊(2.96分)。不满意接受疾病教育和咨询的患者比例在nAMD组(31%)高于DME组(11%;P < 0.01)。眼科医生高估了患者认为注射是必要的程度(平均李克特评分3.41 vs 3.00;P < 0.01),患者在接受治疗时遇到保险障碍(3.00 vs 2.46;P < 0.01)。他们高估了第一次注射后患者神经紧张程度(3.40 vs 2.94;P < 0.01),并低估了他们到达约会的难度(2.30 vs 2.64;P < 0.01)。结论:这项研究强调了接受玻璃体内注射的患者所经历的重大负担,并确定了患者和临床医生之间看法不一致的关键领域。针对这些差异进行针对性的教育和咨询可以提高患者的满意度和治疗效果。